Doctors skeptical of cannabis for Parkinson's—but patients use it anyway

Many people living with Parkinson's disease are already using cannabis-based products on their own to manage symptoms, despite the lack of legal prescription options in France. This study surveyed 218 healthcare professionals in France—including doctors, nurses, and other providers—to understand their views on using cannabis and CBD to treat Parkinson's symptoms. The researchers found that acceptability was significantly higher for CBD than for cannabis, suggesting providers see a potential therapeutic role for the non-intoxicating cannabinoid, even if they're more hesitant about whole-plant cannabis.

A striking finding was the gap between different types of healthcare providers: physicians were 87-90% less likely than other providers to support cannabis or CBD use for Parkinson's disease. The primary reason physicians cited was a lack of scientific evidence proving these treatments actually work for this condition. Many providers also expressed concern about cannabis dependence, which reduced their willingness to recommend it. This creates an important challenge—patients are already self-medicating with these products in the absence of medical guidance, while the doctors who could potentially prescribe them remain unconvinced.

If France or other countries decide to include Parkinson's disease in their medical cannabis programs, the findings suggest physicians will need robust clinical evidence and professional training before they're comfortable prescribing these treatments. The gap between patient use and provider acceptance highlights why rigorous research into cannabis for Parkinson's symptoms is urgently needed—both to inform medical practice and to ensure patients have safe, evidence-based options rather than relying on unregulated self-medication.